Clinical data review, interpretation & communication strategy

Clinical data are only useful when someone can say what they mean and defend it. This service joins three activities that are usually done by different people at different times: reviewing the data, deciding what they show, and communicating that conclusion to a specific audience.

• Patient-level medical reviewReview of individual patient profiles (dosing and exposure, adverse events, laboratory values, concomitant medication, tumor assessments, discontinuation) to establish chronology, check clinical plausibility and find what summary tables hide. This includes the medical-review plan, the design of review listings and follow-up questions for sites and data management.
• Study-level efficacy and safety interpretationReading response, time-to-event and safety outputs against the protocol, the statistical analysis plan and what is known about the disease setting: depth and durability of response, maturity of follow-up, adverse-event patterns, dose modifications, exposure–response and subgroup behavior.
• Benefit–risk assessmentA structured judgment of whether the benefits for the intended patients justify the risks, set against the therapies they already have, with the uncertainties stated. In early programs this supports dose selection and go/no-go decisions; later it supports regulatory discussion.
• Scientific narrative and communicationThe story the data support: key messages, the claims you can and cannot make, and the figures and tables that carry them, adapted for a board slide, an investigator briefing, an agency briefing document, a congress abstract or a manuscript outline.

Oncology data rarely resolve cleanly. Response rates depend on who was enrolled and how response was assessed. An early safety signal may reflect the disease as much as the drug. Immature time-to-event data invite over-interpretation, and an attractive efficacy number can sit on top of an unfavorable dose or tolerability profile.

Misreading the data is expensive: a program advanced on a fragile signal, or dropped on a misunderstood one. A sound result that is communicated poorly can lose a partner, a financing or a regulator’s confidence. The review, the interpretation and the communication have to agree with one another.

• An interim or final readout is approaching,and leadership needs to know in advance what each outcome would mean and how it will be explained.
• Efficacy and safety tell different storiesResponses look encouraging, but dose reductions, discontinuations or particular toxicities complicate the picture.
• A regulatory or partnering discussion depends on the data,and the clinical case should be stated clearly and tested before others test it.
• The team has data but no shared readingInternal functions and vendors interpret the same outputs differently.
• Medical review needs a frameworkListings are produced, but no one is sure they answer the clinical questions.

1. Frame the questions We start from the protocol objectives, the decision ahead and the audience, not from whichever tables happen to exist.
2. Review at patient level Cross-domain review of the profiles that drive the conclusions: responders, long-term treatment, early discontinuations, dose modifications and serious or unusual events. Findings are logged with their evidence and ranked by clinical consequence.
3. Interpret at study level We test conclusions against the analysis plan and the disease context, and separate what the data show, what they suggest and what they cannot support. We identify the analyses or data cuts that would change confidence.
4. Assess benefit–risk Efficacy and safety are set against the intended population and its alternatives, with the uncertainty stated.
5. Build the communication Narrative, key messages and specifications for figures and tables, adapted to leadership, regulatory and scientific audiences, with preparation for the hardest questions.

• A medical-review plan, review-listing specifications and an issue log ranked by clinical consequence
• A written interpretation memorandum covering efficacy, safety, exposure and dose findings, with their limitations
• A benefit–risk assessment with explicit uncertainties
• A scientific narrative with key messages, and specifications for the supporting figures and tables
• Audience-specific drafts and briefings for leadership and the board, for regulators, and for scientific forums such as an abstract, presentation or manuscript outline, as scoped
• A list of anticipated questions with proposed responses

• StructureReview-plan advisory, a defined review-and-interpretation project around a data cut, or ongoing medical-review support. Any continuing medical-monitoring responsibility is agreed explicitly.
• What we need from youThe protocol and analysis plan, data definitions, and authorized extracts, listings or outputs shared through an agreed information-handling process. Synthetic or de-identified material can be used to design the review before live data are shared.
• Roles and limitsStatistical analysis and programming are done by your statisticians and programmers; we specify and interpret. Our review does not replace the sponsor’s safety-reporting obligations or the responsibilities of the study’s medical monitor and safety physician.
• AI-assisted reviewThe core service is physician-led. Where AI-assisted review is considered, it is scoped separately as a defined pilot, and every finding is reviewed by a qualified clinician.